title: Drug-induced lupus erythematosus.
abstract: Drug-induced lupus erythematosus (DI-LE) is defined as an entity characterized by clinical manifestations and immunopathological serum findings similar to those of idiopathic lupus but which is temporally related to drug exposure and resolves after withdrawal of the implicated drug. Similarly to idiopathic lupus, DI-LE can be divided into systemic LE, subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE) and cutaneous LE tumidus. DI-SCLE is the most frequent variant of drug-induced cutaneous LE and presents mainly with annular-polycyclic lesions; the clinical picture is often widespread, with involvement of the lower legs that are usually spared in idiopathic SCLE. ANA and anti-Ro/SSA antibodies are typically present, whereas antihistone antibodies are uncommonly found. We have recently addressed the question whether DI-SCLE differs significantly from its idiopathic counterpart by virtue of clinical features and, based on our findings, we have suggested that the frequent occurrence of malar rash and bullous, erythema multiforme-like and vasculitic manifestations can be regarded as the hallmark of DI-SCLE. In contrast, the histology is not a useful diagnostic criterion for DI-SCLE, considering that the typical pattern of lichenoid interface dermatitis is seen only in the early stage of disease and tissue eosinophilia does not represent a differentiating histopathological feature. DI-CCLE and DI-LE tumidus, albeit possibly misdiagnosed, are rarely observed and are characterized by classic discoid lesions and erythematous-oedematous plaques on sun exposed areas, respectively. Management of DI-LE is based on the discontinuation of the offending drug; topical and/or systemic corticosteroids and other immunomodulating/immunosuppressive agents should be reserved for resistant cases.
authors.affiliation: Operative Unit of Dermatology Department of Pathophysiology and Transplantation University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy - angelovalerio.marzano@policlinico.mi.it.
authors.forename: A V
authors.initials: AV
authors.lastname: Marzano
authors.forename: S
authors.initials: S
authors.lastname: Tavecchio
authors.forename: C
authors.initials: C
authors.lastname: Menicanti
authors.forename: C
authors.initials: C
authors.lastname: Crosti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000097:blood; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007866:Leg / Q000473:pathology; D008178:Lupus Erythematosus, Cutaneous / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology*; D008179:Lupus Erythematosus, Discoid / Q000209:etiology / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060726:Torso / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000974:Antibodies, Antinuclear; D015415:Biomarkers; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents